Hengrui and Kailera report positive phase 3 results for dual GLP-1/GIP agonist in obesity treatment
HRS9531 achieves significant weight reduction in Phase 3 trial, with plans for NDA submission in China and global development as…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.